Is PureTech Health plc (PRTC) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 5.5% / 30% | 90.5% / 30% | 0.4% / 30% | 525.35% / 5% | ✗ NOT HALAL |
| DJIM | 5.5% / 33% | 90.5% / 33% | 0.4% / 33% | 525.35% / 5% | ✗ NOT HALAL |
| MSCI | 3.7% / 33% | 61.0% / 33% | 0.3% / 33% | 525.35% / 5% | ✗ NOT HALAL |
| S&P | 5.5% / 33% | 90.5% / 33% | 0.4% / 33% | 525.35% / 5% | ✗ NOT HALAL |
| FTSE | 3.7% / 33% | 61.0% / 33% | 0.3% / 50% | 525.35% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | -2589.5% | |
| Net Margin | 793.0% | |
| Return on Equity (ROE) | 9.4% | |
| Return on Assets (ROA) | -13.0% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$134M |
| Free Cash Flow | -$134M |
| Total Debt | $22M |
| Debt-to-Equity | 44.3 |
| Current Ratio | 8.5 |
| Total Assets | $603M |
Price & Trading
| Last Close | $15.75 |
| 50-Day MA | $17.47 |
| 200-Day MA | $17.49 |
| Avg Volume | 3K |
| Beta | 0.7 |
|
52-Week Range
$13.30
| |
About PureTech Health plc (PRTC)
PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. It is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. The company also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; and delivers transformative medicines for patients with psychiatric and neurological conditions. In addition, the company develops hydrogels to enable the oral administration of peptide therapeutics in preclinical development; oral therapies based on defined bacterial consortia that is in phase 3 clinical stage; and engineering hematopoietic stem cells to enable targeted therapies for patients with blood cancers. Further, it develops voice-based technology platform that detects changes in the sound of voice that are linked with health conditions, including depression, anxiety, and respiratory disease. The company was incorporated in 2015 and is based in Boston, Massachusetts.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is PureTech Health plc (PRTC) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), PureTech Health plc is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is PureTech Health plc's debt ratio?
PureTech Health plc's debt ratio is 5.5% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 3.7%.
What are PureTech Health plc's key financial metrics?
PureTech Health plc has a market capitalization of $372M, trailing P/E ratio of 9.0, and revenue of $4M. Return on equity stands at 9.4%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.